Drug Profile
DS 3078
Alternative Names: DS-3078; DS-3078aLatest Information Update: 02 Oct 2021
Price :
$50
*
At a glance
- Originator Daiichi Sankyo Company
- Class Antineoplastics
- Mechanism of Action MTORC1 protein inhibitors; MTORC2 protein inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Discontinued Lymphoma; Solid tumours
Most Recent Events
- 31 Oct 2012 Phase-I clinical trials in Lymphoma in European Union (PO)
- 31 Oct 2012 Phase-I clinical trials in Solid tumours in European Union (PO)
- 01 Apr 2012 Phase-I clinical trials in Lymphoma in USA (PO)